Indication
Relapse/Recurrence
6 clinical trials
12 products
1 drug
Product
LYL797Clinical trial
A Phase 1 Study to Assess the Safety and Efficacy of LYL797, ROR1-Targeting CAR T Cells, in Adults With Relapsed and/or Refractory Solid-Tumor MalignanciesStatus: Recruiting, Estimated PCD: 2025-03-01
Product
BST-236Clinical trial
A Phase 2, Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults Unfit for Intensive Chemotherapy With Relapsed or Refractory AML or Higher-Risk Myelodysplastic SyndromesStatus: Active (not recruiting), Estimated PCD: 2023-12-14
Clinical trial
A Prospective, Multicenter Clinical Study on The Safety and Efficacy of Avapritinib in The Treatment of Relapsed/Refractory Pediatric Core Binding Factor Acute Myeloid Leukemia (CBF-AML) With KIT MutationStatus: Recruiting, Estimated PCD: 2026-03-01
Product
AvapritinibProduct
AzacitidineProduct
DecitabineProduct
IdarubicinProduct
CytarabineClinical trial
Utilizing Perioperative Variation Trends of Circulating Tumor Cells and Tumor Pathological Characteristics as a Combined Relapse Prediction Model for Resectable Non-Small Cell Patients - a Prospective Clinical Feasibility TrialStatus: Recruiting, Estimated PCD: 2028-07-31
Product
CisplatinClinical trial
A Randomized Non Comparative Phase II Study of Lacutamab With GemOx Versus GemOx Alone in Relapsed/Refractory Patients With Peripheral T-cell LymphomaStatus: Recruiting, Estimated PCD: 2025-01-30
Product
LacutamabDrug
GemcitabineProduct
OxaliplatineClinical trial
Low-Dose Decitabine Plus Anti-PD-1 Treatment for Relapsed/Refractory Diffuse Large B Cell Lymphoma With Extranodal (Esp. Central Nervous System) Involvement: A PhaseⅡClinical TrialStatus: Recruiting, Estimated PCD: 2025-03-01
Product
Low-Dose Decitabine